Management of CNS Toxoplasmosis
The first-line treatment for CNS toxoplasmosis is pyrimethamine plus sulfadiazine plus leucovorin (folinic acid), continued for at least 6 weeks in acute therapy, followed by lifelong secondary prophylaxis in HIV-infected patients. 1
Primary Treatment Regimen
Standard Therapy (First-Line)
For HIV-infected patients with acquired CNS toxoplasmosis:
- Pyrimethamine: Loading dose of 2 mg/kg/day for 3 days, then 1 mg/kg/day 1
- Sulfadiazine: 25-50 mg/kg/dose four times daily 1
- Leucovorin (folinic acid): 10-25 mg/day - must always be given with pyrimethamine 1
Duration: Continue acute therapy for 6 weeks, assuming clinical and radiological improvement 1. Longer courses may be required for extensive disease or poor response after 6 weeks.
Alternative Regimens for Sulfa Allergy
If sulfadiazine cannot be tolerated due to hypersensitivity:
- Clindamycin: 5.0-7.5 mg/kg orally 4 times daily (maximum 600 mg/dose) plus pyrimethamine and leucovorin 1
Other alternatives used in adults (but not well-studied in children):
- Atovaquone (1,500 mg orally twice daily with meals) plus pyrimethamine and leucovorin 1
- Trimethoprim-sulfamethoxazole (5 mg/kg trimethoprim plus 25 mg/kg sulfamethoxazole IV or orally twice daily) alone 1
- Azithromycin (900-1,200 mg/day) with pyrimethamine and leucovorin 1
Adjunctive Corticosteroid Therapy
Corticosteroids should be used selectively and discontinued as soon as possible due to immunosuppressive effects 1:
- Indications: CSF protein >1,000 mg/dL OR focal lesions with substantial mass effect 1
- Regimen: Dexamethasone or prednisone (1 mg/kg/day divided twice daily) 2
- Timing: If steroids are used, initiate after 72 hours of anti-Toxoplasma therapy 2
- Duration: Continue until CSF protein <1 g/dL or resolution of severe mass effect 2
Recent case evidence supports that pyrimethamine-clindamycin combined with steroids can improve outcomes in cerebral toxoplasmosis with severe edema 3.
Monitoring and Toxicity Management
Hematologic Monitoring
Complete blood count must be performed:
The primary toxicity of pyrimethamine is reversible bone marrow suppression (neutropenia, anemia, thrombocytopenia) 1.
Leucovorin Management
- Always administer leucovorin with pyrimethamine 1
- Increase leucovorin doses if marrow suppression occurs 1
- Continue leucovorin for 1 week after pyrimethamine discontinuation due to pyrimethamine's long half-life 1
Sulfadiazine Adverse Effects
Watch for: rash, fever, leukopenia, hepatitis, gastrointestinal symptoms, and crystalluria 1
Response Assessment and Brain Biopsy
Brain biopsy should be considered when:
- Early neurologic deterioration despite empiric treatment 1
- Failure to respond to anti-Toxoplasma therapy after 10-14 days 1
Definitive diagnosis requires histologic or cytologic confirmation showing leptomeningeal inflammation, microglial nodules, gliosis, and Toxoplasma cysts 1.
Secondary Prophylaxis (Chronic Maintenance Therapy)
Lifelong suppression is indicated after completing initial therapy in HIV-infected patients to prevent recurrence 1:
- Same medications as acute therapy but at reduced frequency
- Pyrimethamine-sulfadiazine-leucovorin provides dual protection against both toxoplasmosis and PCP 4
Discontinuing Secondary Prophylaxis
Secondary prophylaxis can be discontinued in patients who:
- Successfully completed initial therapy
- Remain asymptomatic
- Have sustained CD4+ count >200 cells/µL for ≥6 months on HAART 4
Restart prophylaxis if CD4+ count decreases to <200 cells/µL 4
Special Populations
Congenital Toxoplasmosis
Different dosing and duration (12 months total therapy) - requires specialist consultation 1
Immunocompetent Patients
CNS toxoplasmosis can occur in immunocompetent individuals with atypical presentations 5, 6. Treatment with sulfamethoxazole-trimethoprim has shown efficacy in these cases 5.
Common Pitfalls
- Forgetting leucovorin: Always administer with pyrimethamine to prevent bone marrow toxicity
- Premature steroid use: Wait 72 hours after starting anti-Toxoplasma therapy before adding steroids
- Inadequate monitoring: Weekly CBCs are essential during daily pyrimethamine therapy
- Stopping leucovorin too early: Continue for 1 week after stopping pyrimethamine
- Negative serology: Does not exclude diagnosis - cases have been reported in seronegative patients 1
Neuroimaging Characteristics
Typical findings include multiple, bilateral, ring-enhancing lesions in basal ganglia and cerebral corticomedullary junction 1. MRI is more sensitive than CT 1. Recent systematic review confirms CT and MRI remain essential for diagnosis and follow-up 7.